United Therapeutics (UTHR) Set to Announce Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect United Therapeutics to post earnings of $5.63 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period last year, the company earned $2.67 EPS. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. On average, analysts expect United Therapeutics to post $23 EPS for the current fiscal year and $25 EPS for the next fiscal year.

United Therapeutics Stock Down 0.9 %

Shares of UTHR opened at $233.85 on Monday. The stock has a fifty day simple moving average of $233.74 and a two-hundred day simple moving average of $228.76. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52. United Therapeutics has a 52-week low of $204.44 and a 52-week high of $261.54.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. Finally, Wedbush reissued an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $294.25.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,869,150.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,869,150.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The disclosure for this sale can be found here. Insiders sold 136,990 shares of company stock worth $32,239,641 in the last three months. 12.50% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.